FDA Advisors Reject Arcoxia
On April 12th, a Food and Drug Administration, FDA, advisory panel of experts rejected Merck’s drug, Arcoxia, in a 20-1 vote. It is a non-binding recommendation that the FDA should not approve the drug for the U.S. market. The FDA will be taken as advice and one factor to consider when the FDA is makes its decision whether or not to... Read more








